Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol

Description

ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of binge eating disorder (BED) in adults.

Conditions

Binge-Eating Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of binge eating disorder (BED) in adults.

A Phase 3, Randomized, Double-blind, Placebo-Controlled Trial of Solriamfetol in Adults With Binge Eating Disorder (BED)

Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol

Condition
Binge-Eating Disorder
Intervention / Treatment

-

Contacts and Locations

Encino

Clinical Research Site, Encino, California, United States, 91316

Newport Beach

Clinical Research Site, Newport Beach, California, United States, 92660

San Diego

Clinical Research Site, San Diego, California, United States, 92103

Clermont

Clinical Research Site, Clermont, Florida, United States, 34711

Jacksonville

Clinical Research Site, Jacksonville, Florida, United States, 32256

Orlando

Clinical Research Site, Orlando, Florida, United States, 32801

Orlando

Clinical Research Site, Orlando, Florida, United States, 32806

Marietta

Clinical Research Site, Marietta, Georgia, United States, 30060

Overland Park

Clinical Research Site, Overland Park, Kansas, United States, 66210

Methuen

Clinical Research Site, Methuen, Massachusetts, United States, 01844

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Primary diagnosis of BED according to DSM-5 criteria.
  • * Provides written informed consent to participate in the study before the conduct of any study procedures.
  • * Male or female, aged 18 to 55 inclusive.
  • * Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription.
  • * Unable to comply with study procedures.
  • * Medically inappropriate for study participation in the opinion of the investigator.

Ages Eligible for Study

18 Years to 55 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Axsome Therapeutics, Inc.,

Study Record Dates

2025-12